nezkil syrup uses

Written by Dr Taha Murtaza [PharmD, DOW University Of Health Sciences (DUHS)], Karachi, Pakistan)

Generic:

Linezolid

Manufacturer:

Continental Pharmaceuticals

Prescription drug?

Yes

Avaialable dosage forms:

Nezkil 600mg infusion: Each 300ml contains linezolid.....600mg

Nezkil 200mg infusion: Each 100ml contains linezolid.....200mg

Nezkil 600mg tablet: Each tablet contains linezolid.....600mg

Nezkil 400mg tablet: Each tablet contains linezolid.....400mg

Nezkil suspensipn: Each 5ml contains linezolid.....400mg

Pharmacological class:

Protein synthesis inhibitor (50s-protein subunit inhibitor)

Therapeutic class:

Antibiotic

Chemistry:

Synthetic compound belongs to the oxazolidinone class

1. Indication: Vancomycin-resistant enterococcus faecium infections, including cases with concurrent bacteremia.

   
   

   Dose and route of administration:

   Paeds (birth-11years):

   10mg/kg IV/PO q8h.

   Adults:

   600mg IV/PO q12 h

   Recommended duration of treatment (consecutive days):

   14 to 28

   
   

2. Indication: Nosocomial pneumonia caused by staphylococcus aureus (methicillin-susceptible and resistant strains) or streptococcus pneumonia (including multi-drug resistant strains)

   Dose:

   Paeds: (Birth-11years):

   10mg/kg IV/PO q8h.

   Adult (12 years older)

   600mg IV/PO q12h

   Recommended duration of treatment (consecutive days):

   10 to 14 days.

   
   

3. Indication: Complicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible and resistant strains), streptococcus pyogenes, or Streptococcus agalactia.

   
   

   Dose:

   Paeds: (Birth-11years)

   10mg/kg IV/PO q8h.

   Adult (12 years older)

   600mg IV/PO q12h

   Recommended duration of treatment (consecutive days): 10 to 14 days.

   
   

4. Indication: Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible and resistant strains).

   
   

   Dose:

   Paeds: (birth-11years age)

   < 5 years: 10mg/kg PO q8h

   5-11 years: 10mg/kg PO q12h

   Adolescents:

   600mg PO q12h

   Adults: 400mg PO q12h

   Recommended duration of treatment (consecutive days):

   10 to 14 days

   
   
   
   

5. Community-acquired pneumonia caused by streptococcus pneumonia (including multi-drug resistant strains) including cases with concurrent bacteremia or staphylococcus aureus (methicillin-susceptible strains only)

   
   

   Dose:

   Paeds: (Birth-11years)

   10mg/kg IV/PO q8h.

   Adult (12 years older)

   600mg IV/PO q12h

   Recommended duration of treatment (consecutive days):

   10 to 14 days.

Special population:

Geriatrics:

No dose adjustment is required.

Gender:

The same dose is used in males and females.

Renal insufficiency:

No dose adjustment is required.

Hepatic insufficiency:

In patients with child-pugh class A or B i.e. mild-moderate hepatic dysfunction, no dose adjustment is required but patients with severe hepatic dysfunction, pharmacokinetics have not been evaluated.

Pregnancy:

FDA has called linezolid a category C antibiotic for the use in pregnant women means it can only be used by pregnant mothers in case where emergency is required i.e. benefits surpasses side effects.

Lactation:

If alternate antibiotic is available, then kindly refused this in lactating mothers.

Contra-indications:

In patients with hypersensitivity to linezolid or any of the components of the product.

Side-effects:

Common:

• Diarrhea

• Headache

• Nausea

Others:

• Vomiting

• insomnia

• Constipation

• rash

• Dizziness

• fever

• oral moniliasis

• vaginal moniliasis

• hypertension

• dyspepsia

• localized abdominal pain

• pruritis

• tongue discoloration

Precautions:

• Patients with pseudomembranous colitis should avoid linezolid

• The superinfection produced by clostridium difficle should be managed during treatment with linezolid.

• Thrombocytopenia could occur, and platelets of patients should be monitored.

Interactions:

• With Mono-amino-oxidase inhibitors

• With adrenergic agents

• With serotonergic agents.